Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.

Autor: Mariano Provencio, Pilar Sabín, Jose Gomez-Codina, Maria Torrente, Virginia Calvo, Marta Llanos, Josep Gumá, Cristina Quero, Ana Blasco, Miguel Angel Cruz, David Aguiar, Francisco García-Arroyo, Javier Lavernia, Natividad Martinez, Manuel Morales, Alvaro Saez-Cusi, Delvys Rodriguez, Luis de la Cruz, Jose Javier Sanchez, Antonio Rueda, GOTEL (Spanish Lymphoma Oncology Group)

Publikováno v: PLoS ONE, Vol 12, Iss 5, p e0177204 (2017)

BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The pri

Externí odkaz: https://doaj.org/article/6e236207a74245ef906d5faa5f1d0dde

mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group

Autor: Provencio, Mariano, Rodríguez, Marta, Cantos, Blanca, Sabín, Pilar, Quero, Cristina, García-Arroyo, Francisco R., Rueda, Antonio, Maximiano, Constanza, Rodríguez-Abreu, Delvys, Sánchez, Antonio, Silva, Javier, García, Vanesa, GOTEL (Spanish Lymphoma Oncology Group)

Publikováno v: RUNA. Repositorio da Consellería de Sanidade e Sergas
Servizo Galego de Saúde (SERGAS)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Oncotarget

Purpose: To determine the feasibility of mRNAs (C-MYC, BCL-XL, BCL-6, NF-κβ, PTEN and AKT) in exosomes of plasma as a liquid biopsy method for monitoring and prognostic evolution in B-cell lymphomas. Patients and Methods: Exosomes were isolated fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c497879bc1df3ae7ca865662e52295
https://doi.org/10.18632/oncotarget.16435

Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

Autor: Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR, de la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A, Gotel (Spanish Lymphoma Oncology Group)

Publikováno v: Leukemia & lymphoma
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We set out to evaluate the role of consolidation with Yttrium-90 ibritumomab tiuxetan in patients with intermediate-and high-risk FL after four cycles of CHOP-R (cyclophosp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::836a7319ad50e448ba4542aa4951ffea
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2377

Mutational profile of primary breast diffuse large B-cell lymphoma.

Autor: Franco F; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain., González-Rincón J; Group of Research in Lymphomas, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Lavernia J; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.; Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain., García JF; Pathology Department, MD Anderson Cancer Center, Madrid, Spain., Martín P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain., Bellas C; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain., Piris MA; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Pedrosa L; Group of Research in Lymphomas, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain., Miramón J; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.; Medical Oncology Department, Hospital Serranía de Ronda, Málaga, Spain., Gómez-Codina J; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.; Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Rodríguez-Abreu D; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain., Machado I; Pathology Department, Instituto Valenciano de Oncología, Valencia, Spain., Illueca C; Pathology Department, Instituto Valenciano de Oncología, Valencia, Spain., Alfaro J; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.; Medical Oncology Department, Instituto Oncológico de Kutxa, Donostia, Spain., Provencio M; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain., Sánchez-Beato M; GOTEL (Spanish Lymphoma Oncology Group), Madrid, Spain.; Group of Research in Lymphomas, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Publikováno v: Oncotarget [Oncotarget] 2017 Oct 24; Vol. 8 (61), pp. 102888-102897. Date of Electronic Publication: 2017 Oct 24 (Print Publication: 2017).